Edition:
United Kingdom

Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

6.40USD
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
$6.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
142,420
52-wk High
$8.55
52-wk Low
$2.45

Chart for

About

Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The Company is engaged in discovering and developing gene therapeutics for ophthalmic diseases. It is focused on developing gene therapy programs to address unmet medical needs of diseases, such as wet age-related macular... (more)

Overall

Beta: --
Market Cap(Mil.): $153.67
Shares Outstanding(Mil.): 43.29
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Adverum Biotechnologies Prices $60 Mln Public Offering Of Stock

* ADVERUM BIOTECHNOLOGIES ANNOUNCES PRICING OF $60 MILLION PUBLIC OFFERING OF COMMON STOCK

08 Feb 2018

BRIEF-Adverum Biotechnologies Announces Proposed Public Offering

* ADVERUM BIOTECHNOLOGIES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

07 Feb 2018

BRIEF-Adverum Biotechnologies Extends Collaboration Agreement With Editas Medicine

* ANNOUNCES EXTENSION OF ITS COLLABORATION AGREEMENT WITH EDITAS MEDICINE INC

25 Jan 2018

BRIEF-Adverum Biotechnologies Provides 2018 Outlook

* ADVERUM BIOTECHNOLOGIES INC - ADVERUM'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $186.6 MILLION AS OF SEPTEMBER 30, 2017.

04 Jan 2018

BRIEF-Highbridge Capital Reports 5.55 Pct Passive Stake In Adverum Biotechnologies

* HIGHBRIDGE CAPITAL MANAGEMENT LLC REPORTS 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF DECEMBER 5 - SEC FILING Source text for Eikon: (http://bit.ly/2iwSEnw) Further company coverage:

06 Dec 2017

BRIEF-Adverum Begins Patient Enrollment In Advance Phase 1/2 Clinical Trial

* ADVERUM BIOTECHNOLOGIES BEGINS PATIENT ENROLLMENT IN THE ADVANCE PHASE 1/2 CLINICAL TRIAL FOR A1AT DEFICIENCY

05 Dec 2017

BRIEF-‍Adage Capital Partners Reports A 5.55 Percent Passive Stake In Adverum Biotechnologies As Of Nov 17, 2017

* ‍ADAGE CAPITAL PARTNERS GP, L.L.C REPORTS A 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF NOVEMBER 17, 2017 - SEC FILING​ Source text: (http://bit.ly/2hXgpom) Further company coverage:

27 Nov 2017

BRIEF-Adverum Biotechnologies posts Q3 loss of $0.32 per share

* Adverum biotechnologies reports third quarter 2017 financial results and provides corporate update

08 Nov 2017

BRIEF-Adverum Biotechnologies says has increased size of board to eight members

* Adverum Biotechnologies Inc - increased size of board to eight members - SEC filing Source text: [http://bit.ly/2eKPWc0] Further company coverage:

07 Sep 2017

Earnings vs. Estimates